Drug Interactions between colchicine and zanubrutinib

Consumer information for this interaction is not currently available.

MONITOR CLOSELY: Coadministration of zanubrutinib with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Serious and fatal hemorrhagic events have been reported during zanubrutinib monotherapy. Grade 3 or higher bleeding events including intracranial and gastrointestinal hemorrhage, hematuria, and hemothorax have been reported in up to 4.6% of patients treated with zanubrutinib monotherapy, with fatalities occurring in up to 0.3% of patients. Overall, bleeding events of any grade, including purpura and petechiae, have occurred in patients both with and without concomitant antiplatelet or anticoagulation therapy. Coadministration of zanubrutinib with antiplatelet or anticoagulant medications may potentiate the risk of hemorrhage. The mechanism for the bleeding events is not well understood, although treatment with zanubrutinib commonly causes thrombocytopenia. Grade 3 or 4 cytopenias including neutropenia, thrombocytopaenia, and anemia have been reported during treatment with zanubrutinib monotherapy.

MANAGEMENT: Use of zanubrutinib, either alone or concomitantly with other medications that interfere with platelet function or coagulation may potentiate risk of bleeding complications. Concomitant use should be done with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Discontinue zanubrutinib if intracranial hemorrhage of any grade occurs. Refer to the product labeling further dosage adjustment, and/or withholding treatment is advised if Grade 3 or higher adverse reactions occur. Additional consultation with individual package labeling, as well as relevant institutional protocols, may be advisable for further guidance.